Pfizer (PFE) Stock Price, Chart, Company Profile & AI Analysis

Key Takeaways

• Pfizer shares have climbed roughly 9% over the past 30 days, a move below the 10% threshold that keeps the stock in a measured recovery rather than a sharp breakout.
• Second-quarter 2026 results topped estimates, with revenue of about $15.0 billion and adjusted EPS of $0.77, and management raised the midpoint of its full-year revenue guidance to $60.5–$62.5 billion.
• Non-COVID products are carrying growth: Padcev, Nurtec ODT/Vydura, and Lorbrena posted double-digit gains while Comirnaty and Paxlovid sales continued to fade.
• A dividend of $0.43 per share per quarter, equating to a roughly 5.9% yield, and more than $7 billion in cumulative cost reductions remain central to the investment case.
• The defining challenge is a looming patent cliff for Eliquis, Xeljanz, Ibrance, and Xtandi, which management is working to offset with oncology and obesity pipeline assets.

Current Market Snapshot

Pfizer shares have recovered to roughly $30, up about 9% over the last 30 days after trading near $27.66 a month earlier. The advance has been steady rather than explosive, reflecting a broader rotation toward higher-yielding, defensive healthcare names as investors weigh valuation and income against growth. The stock carries a forward earnings multiple well below its trailing figure, which is inflated by restructuring charges and intangible-asset impairments, and a dividend yield near 6% that compares favorably with the broader S&P 500. While the shares remain well below their pandemic-era highs, improved execution and a denser pipeline have gradually rebuilt investor confidence.

Pfizer (PFE) Business Overview and Competitive Position

Pfizer is one of the world's largest research-based biopharmaceutical companies, spanning vaccines, oncology, immunology, inflammation, rare diseases, and primary-care medicines. Its portfolio includes the blood thinner Eliquis, the breast-cancer drug Ibrance, the prostate-cancer treatment Xtandi, the pneumococcal vaccine franchise Prevnar, the transthyretin-amyloidosis therapy Vyndaqel family, and the COVID-19 products Comirnaty and Paxlovid. Strategic acquisitions have reshaped the business, including Seagen in oncology, Biohaven (Nurtec ODT) in migraine, and Metsera in obesity. Investors follow the stock for its scale, diversified pipeline, and income, while watching closely how new oncology and weight-loss assets perform as older blockbusters approach loss of exclusivity.

Recent Developments Driving PFE

Pfizer's second-quarter 2026 earnings were a key catalyst. Revenue of roughly $15.03 billion and adjusted EPS of $0.77 both beat consensus, and the company raised the midpoint of its full-year revenue guidance while trimming its COVID-19 revenue expectations to about $4 billion. Growth is increasingly concentrated in launched and acquired products: Padcev, a bladder-cancer therapy, grew about 39% operationally in the first quarter, while Nurtec and Lorbrena also expanded at double-digit rates.

Cost discipline is reinforcing the bottom line. Management has removed about $7.2 billion from the cost base over three years and announced an additional $2.5 billion in net savings targeted for 2027 through 2029, supporting margins and pipeline funding. On the pipeline front, Pfizer has reported positive data across oncology and immunology, including Elrexfio in multiple myeloma, Talzenna in prostate cancer, and early-stage obesity assets, while presenting 57 abstracts at IDWeek 2026 covering pneumococcal, RSV, Lyme, and COVID-19 vaccine research. A multibillion-dollar oncology collaboration with Innovent and patent settlements extending Vyndamax exclusivity to 2031 have further supported sentiment.

Trending AI Robots

For traders seeking a data-driven view of the market, Tickeron's Trending AI Robots page curates a focused selection of its most relevant automated trading bots. Tickeron operates hundreds of AI-driven trading bots that monitor thousands of tickers, but only top-performing and most relevant strategies appear in this section, helping users filter the noise. These bots vary widely in strategy, timeframe, and performance metrics, from short-term technical models to longer-horizon approaches. Browsing the page offers a practical way to explore how algorithmic strategies are positioned across equities like Pfizer and the broader market, and can be a useful starting point for investors evaluating systematic approaches.

2026 Outlook and What Investors Should Watch

Investors should monitor Pfizer's ability to replace patent-cliff revenues with new products. Eliquis and Xeljanz face U.S. exclusivity losses, with Ibrance and Xtandi to follow, making commercial follow-through in Padcev and Nurtec and the ramp of oncology and obesity launches essential. Key catalysts include the event-driven Phase 3 readout for mevrometostat in metastatic prostate cancer and progress on the obesity program, where berobenatide has ten planned Phase 3 studies and a first approval targeted for 2028. Macroeconomic and policy factors, including drug-pricing reform, the 340B program, and tariffs, also remain relevant. Management has signaled confidence in maintaining the dividend, but balance-sheet leverage and the pace of pipeline conversions will be central to whether the stock can sustain its recovery.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations